These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28550830)

  • 1. [Biologicals and Biosimilars: Gaps in the Pharmacovigilance System in Portugal].
    Portela MC; Sinogas C; Almeida FA; Baptista-Leite R; Castro-Caldas A
    Acta Med Port; 2017 Mar; 30(3):205-212. PubMed ID: 28550830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologicals and biosimilars: safety issues in Europe.
    Portela MDCC; Sinogas C; Albuquerque de Almeida F; Baptista-Leite R; Castro-Caldas A
    Expert Opin Biol Ther; 2017 Jul; 17(7):871-877. PubMed ID: 28540760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Traceability of biologicals: present challenges in pharmacovigilance.
    Vermeer NS; Spierings I; Mantel-Teeuwisse AK; Straus SM; Giezen TJ; Leufkens HG; Egberts TC; De Bruin ML
    Expert Opin Drug Saf; 2015 Jan; 14(1):63-72. PubMed ID: 25369769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
    Felix T; Jordan JB; Akers C; Patel B; Drago D
    Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice.
    Vermeer NS; Giezen TJ; Zastavnik S; Wolff-Holz E; Hidalgo-Simon A
    Clin Pharmacol Ther; 2019 Apr; 105(4):962-969. PubMed ID: 30460997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view.
    Pineda C; Caballero-Uribe CV; de Oliveira MG; Lipszyc PS; Lopez JJ; Mataos Moreira MM; Azevedo VF
    Clin Rheumatol; 2015 Apr; 34(4):635-40. PubMed ID: 25673060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Knowledge about Biosimilars in Primary Care: a study by the Spanish Society of Primary Care Physicians (SEMERGEN)].
    Micó-Pérez RM; Payares-Herrera C; Palomo-Jiménez PI; Sánchez-Fierro J; Avendaño-Solá C; Llisterri-Caro JL
    Semergen; 2018 Sep; 44(6):380-388. PubMed ID: 29459003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: pharmacovigilance and risk management.
    Zuñiga L; Calvo B
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar medical products - licensing, pharmacovigilance and interchangeability.
    Grozdanova A; Netkovska KA; Sterjev Z; Naumovska Z; Zarevski R; Dimovski A; Suturkova L
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016; 37(1):27-36. PubMed ID: 27442414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interchangeability of biological products in the Brazilian Unified National Health System (SUS): the main regulatory challenges].
    Ferreira Neto PTP; Nunes PHC; Vargas MA
    Cad Saude Publica; 2019; 35(10):e00053519. PubMed ID: 31618379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance of Biologics in a Multisource Environment.
    Sagi S; Cohen HP; Woollett GR
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1249-1254. PubMed ID: 29172979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biopharmaceuticals safety perception in Slovakia: considerations and real-life pharmacovigilance data.
    Lassanova M; Liskova S; Tisonova J; Fundarkova S; Lassan S
    Bratisl Lek Listy; 2021; 122(7):443-448. PubMed ID: 34161110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
    de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
    J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System.
    Singh A; Kalaivani M; Srivastava S; Goyal RK; Gupta SK
    Ther Innov Regul Sci; 2020 May; 54(3):667-680. PubMed ID: 33301154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biosimilars, no generic biologicals!].
    Knuts B
    J Pharm Belg; 2016 Dec; (4):24-29. PubMed ID: 30281245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars: A new scenario in biologic therapies.
    Serra López-Matencio JM; Morell Baladrón A; Castañeda S
    Reumatol Clin; 2017; 13(5):287-293. PubMed ID: 27372258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.